Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 11, 2013, Pages 1417-1422

  Karageorgopoulos, D E ^a   Maraki, S ^b   Vatopoulos, A C ^c,d   Samonis, G ^b   Schito, G C ^e   Falagas, M E ^a,f,g  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^d Iatropolis Diagnostic Center   (Greece)

^e UNIVERSITY OF GENOA   (Italy)

^f MITERA HOSPITAL   (Greece)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ULIFLOXACIN;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; EAR; ESCHERICHIA COLI; GREECE; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEUS MIRABILIS; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; SPUTUM ANALYSIS; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS PYOGENES; THROAT CULTURE; URINALYSIS; URINARY TRACT; URINARY TRACT INFECTION; WILCOXON SIGNED RANKS TEST;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DIOXOLANES; FEMALE; FLUOROQUINOLONES; GREECE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PIPERAZINES; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; URINARY TRACT INFECTIONS;

EID: 84886582854     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1891-z     Document Type: Article

References (19)

1. Walker RC (1999) The fluoroquinolones. Mayo Clin Proc 74:1030-1037
2. Hooper DC (2000) Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 31(Suppl 2):S24-S28
3. Matera MG (2006) Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 19(Suppl 1):20-29
4. Keam SJ, Perry CM (2004) Prulifloxacin. Drugs 64:2221-2234, discussion 35-6
5. Rafailidis PI, Polyzos KA, Sgouros K, Falagas ME (2011) Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. Int J Antimicrob Agents 37:283-290
6. Cai T, Mazzoli S, Addonisio P, Boddi V, Geppetti P, Bartoletti R (2010) Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study. Methods Find Exp Clin Pharmacol 32:39-45
7. Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19. CLSI, Wayne, PA
8. Clinical and Laboratory Standards Institute (CLSI) (2006) Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline. CLSI document M45-A. CLSI, Wayne, PA
9. Montanari MP, Ferrante L, Tili E, Cochetti I, Rossi V, Varaldo PE (2005) Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin. J Chemother 17:138-142
10. 90 for comparison of antibiotic potency. Clin Microbiol Infect 14(Suppl 7):S606 (abstract P2059)
11. Fritsche TR, Biedenbach DJ, Jones RN (2009) Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea. Antimicrob Agents Chemother 53:1221-1224
12. Giannarini G, Tascini C, Selli C (2009) Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Future Microbiol 4:13-24
13. Montanari MP, Mingoia M, Varaldo PE (2001) In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemother 45:3616-3622
14. Prats G, Roig C, Miró E, Navarro F, Mirelis B (2002) In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 21:328-334
15. Gualco L, Schito AM, Schito GC, Marchese A (2007) In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. Int J Antimicrob Agents 29:679-687
16. Thamlikitkul V, Tiengrim S (2010) Comparative in vitro activity of prulifloxacin against bacteria isolated from hospitalized patients at Siriraj Hospital. J Infect Dis Antimicrob Agents 27:61-68
17. Pallecchi L, Riccobono E, Montagnani F, Di Maggio T, Mantengoli E, Pollini S, Rossolini GM (2011) Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin. J Chemother 23:308-309
18. Montanari MP, Tili E, Cochetti I, Mingoia M, Manzin A, Varaldo PE (2004) Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Microb Drug Resist 10:209-217
19. Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, Barbone F, Selli C (2007) Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J Chemother 19:304-308